Skip to main content
SpringerLink
Log in

Nursing Considerations with ALK and ROS1 Inhibitors in NSCLC

  • Chapter
  • First Online:
Book cover Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners

  • 433 Accesses

Abstract

ALK and ROS1 positive NSCLC make up a small subset, around 5–7% of NSCLC overall. However, there are several targeted treatment options available to treat this type of lung cancer, all of which are superior to traditional chemotherapy response rates and survival rates. Testing for these molecular gene aberrations is generally simple and can be resulted quickly. Treatments for ALK and ROS1 positive NSCLC are similar. Side effects of the ALK inhibitors may vary depending on the drug, and nurses must understand the common toxicities and strategies to manage the side effects. Most of the side effects are very manageable and patients can stay on therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 59.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society Facts & Figures 2019. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html. Accessed June 15, 2019.

  2. Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82:179–89.

    Article  Google Scholar 

  3. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcomes of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247.

    Article  CAS  Google Scholar 

  4. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011;17(8):2081.

    Article  CAS  Google Scholar 

  5. Kwak EL, Bang Y-J, Camidge R, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–703.

    Article  CAS  Google Scholar 

  6. Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.

    Article  Google Scholar 

  7. Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.

    Article  CAS  Google Scholar 

  8. Peters S, Camidge R, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38.

    Article  CAS  Google Scholar 

  9. Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–97.

    Article  CAS  Google Scholar 

  10. Shaw AT, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;18:874–6.

    Article  CAS  Google Scholar 

  11. Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917–29.

    Article  CAS  Google Scholar 

  12. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet. 2016;17:234–42.

    Article  CAS  Google Scholar 

  13. Kim D-W, Tisco M, Ahn M-J, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma-kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35:1–11.

    Article  Google Scholar 

  14. Ou SHI, Tiseo M, Camidge DR, et al. Intracranial efficacy of brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase (AKL)-non-small cell lung cancer (NSCLC) and baseline CNS metastases. Poster presented at the Annual Congress of the European Society of Medical Oncology; 8–12, September 2017, Madrid. Poster 1345p.

    Google Scholar 

  15. Shaw AT, Felipe E, Bauer TM, Besse B, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–9.

    Article  CAS  Google Scholar 

  16. Solomon BJ, Besse B, Bauer TM. Lorlatinib in patients with ALK-positive non-small cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–67.

    Article  CAS  Google Scholar 

  17. Lin JJ, Shaw A. Recent advances in targeting of ROS1 in lung cancer. J Thorac Oncol. 2017;12:161–1625.

    Article  Google Scholar 

  18. Marchetti A, Barberis M, Di Lorito A, et al. ROS1 gene fusion in advanced lung cancer in women: a systematic analysis, review of the literature, and diagnostic algorithm. JCO Precis Oncol. 2017;1:1–9.

    Google Scholar 

  19. Gainor Justin F, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol. 2017;1:1–13.. https://doi.org/10.1200/PO.17.00063

    Google Scholar 

  20. Clinicaltrials.gov. Searched ROS1 rearrangement. Accessed 8 June 2018.

    Google Scholar 

  21. Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71.

    Article  Google Scholar 

  22. Lim SM, Kim HR, Lee J-S, et al. Open-label, multicenter, phase II study of ceritinib in patients with no-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35:2613–8.

    Article  CAS  Google Scholar 

  23. Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M. Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. Clin Lung Cancer. 2018;19(2):e151–61.. https://doi.org/10.1016/j.cllc.2017.10.008

    Article  CAS  Google Scholar 

  24. Jacky J, Baik C. Symptom management strategies for patients receiving anaplastic lymphoma kinase inhibitors for non-small cell lung cancer. J Adv Pract Oncol. 2017;8(7):729–35.

    PubMed  PubMed Central  Google Scholar 

  25. Kim D-W, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, et al. Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial. Lancet Oncol. 2016;17(4):452–63.

    Article  CAS  Google Scholar 

  26. Beardslee T, Lawson J. Alectinib and brigatinib: new second-generation ALK inhibitors for the treatment of non-small cell lung cancer. J Adv Pract Oncol. 2018;9(1):94–101.

    PubMed  PubMed Central  Google Scholar 

  27. Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with ALK inhibitors. Curr Oncol. 2014;21(1):19–26.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Beth Eaby-Sandy

Authors
  1. Beth Eaby-Sandy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beth Eaby-Sandy .

Editor information

Editors and Affiliations

  1. Yale Comprehensive Cancer Center, Yale University School of Nursing, New Haven, CT, USA

    Marianne Davies

  2. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Beth Eaby-Sandy

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Eaby-Sandy, B. (2019). Nursing Considerations with ALK and ROS1 Inhibitors in NSCLC. In: Davies, M., Eaby-Sandy, B. (eds) Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. Springer, Cham. https://doi.org/10.1007/978-3-030-16550-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16550-5_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16549-9

  • Online ISBN: 978-3-030-16550-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation